D-methionine methyl ester | 21691-49-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 蛋氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: D-methionine methyl ester
• 英文别名: D-Met-OMe；H-D-Met-OMe；methyl (2R)-2-amino-4-methylsulfanylbutanoate
• CAS: 21691-49-6
• 化学式: C₆H₁₃NO₂S
• 分子量: 163.241
• InChiKey: UIHPNZDZCOEZEN-RXMQYKEDSA-N

物化性质

• 沸点：
  240℃
• 密度：
  1.094
• 闪点：
  99℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  77.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  D-methionine methyl ester 在 ammonium hydroxide 、 氢溴酸 作用下， 生成 D-蛋氨酸
  参考文献：
  名称：

  Tatsuoka; Honjo, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1953, vol. 73, p. 355

  摘要：

  DOI：
• 作为产物：
  描述：

  DL-methionine methyl ester 生成 D-methionine methyl ester
  参考文献：
  名称：

  Trincone, Antonio; Nicolaus, Barbara; Lama, Licia, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1993, vol. 32, # 1, p. 25 - 29

  摘要：

  DOI：

文献信息

• Benzoxazepinones and their use as squalene synthase inhibitors
  申请人：——

  公开号：US20030078251A1

  公开（公告）日：2003-04-24

  There is disclosed a compound represented by the formula [I]: 1 wherein R 1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, —X 1 —X 2 —Ar—X 3 —X 4 —COOH (wherein X 1 and X 4 are a bond or alkylene group, X 2 and X 3 are a bond, —O—, —S—, Ar is divalent aromatic group etc.), R 2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R 3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.

  披露了一种由公式[I]表示的化合物： 1 其中R 1 是可选地取代的1-羧乙基，可选地取代的烷基亚磺酰基，可选地取代的(羧基环烷基)-烷基，—X 1 —X 2 —Ar—X 3 —X 4 —COOH(其中X 1 和X 4 是键或亚烷基，X 2 和X 3 是键，—O—，—S—，Ar是二价芳香族等)，R 2 是可选地由酰氧基和/或羟基取代的烷基，R 3 是烷基，W是卤素原子等，或其盐。该化合物具有降低胆固醇活性和降低甘油三酯活性，用于预防或治疗高脂血症。
• Structurally modified glycyrrhetinic acid derivatives as anti-inflammatory agents
  作者：Ming Bian、Dong Zhen、Qing-Kun Shen、Huan-Huan Du、Qian-Qian Ma、Zhe-Shan Quan

  DOI：10.1016/j.bioorg.2020.104598

  日期：2021.2

  With the aim of finding new anti-inflammatory drugs, a series of new Glycyrrhetinic acid derivatives (1–34) have been designed and synthesized by structural modification, and their anti-inflammatory activities in vitro have been evaluated. The anti-inflammatory activities assay demonstrated that compound 5b suppressed the expression of pro-inflammatory cytokines including IL-6, TNF-α and NO, it also

  以寻找新型抗炎药为目的，通过结构修饰设计合成了一系列新的甘草次酸衍生物（1-34），并对其体外抗炎活性进行了评价。抗炎活性测定表明，化合物 5b 抑制了促炎细胞因子包括 IL-6、TNF-α 和 NO 的表达，它还抑制了 LPS 诱导的 RAW264.7 细胞中 iNOS 和 COX-2 的表达。剂量依赖性方式。此外，蛋白质印迹结果表明化合物 5b 对促炎细胞因子的抑制作用与抑制 NF-κB 和 MAPK 信号通路有关。
• A General One-Pot, Three-Component Mono N-Alkylation of Amines and Amine Derivatives in Lithium Perchlorate/Diethyl Ether Solution
  作者：Akbar Heydari、Hossein Tavakol、Saied Aslanzadeh、Jamshid Azarnia、Nafiseh Ahmadi

  DOI：10.1055/s-2005-861798

  日期：——

  reductive monoalkyl- ation of amines and amine derivatives with aldehydes is reported. Treatment of aldehydes with primary amines, secondary amines, O- trimethylsilylhydroxylamine, and N,N-dimethylhydrazine in lithi- um perchlorate/diethyl ether and trimethylsilyl chloride, followed by BH3·NEt3 reduction, and straightforward workup afforded sec- ondary amines, tertiary amines, N-substituted hydroxylamines

  报道了一种用醛还原单烷基化胺和胺衍生物的有效通用程序。在高氯酸锂/乙醚和三甲基氯硅烷中用伯胺、仲胺、O-三甲基甲硅烷基羟胺和 N,N-二甲基肼处理醛，然后进行 BH3·NEt3 还原，直接后处理得到仲胺、叔胺，N-取代的羟胺和肼，分别。α-氨基酯与醛的还原烷基化选择性地提供相应的N-单烷基化α-氨基酯。
• Sparsomycin analogs. IV. Synthesis and antitumor activity of pyrimidine-5-carboxamides and(E)-.BETA.-(pyrimidin-5-yl)-acrylamides.
  作者：SHOICHI KANATOMO、AKIMORI WADA、MASAKATSU YOMEI、TETSUKO HASE、SOTOO NAGAI、SHIZUO FUKUDA、MOTOHIRO TANAKA、TAKUMA SASAKI

  DOI：10.1248/cpb.36.2042

  日期：——

  Various pyrimidine-5-carboxamides (14, 16, 18, 20, and 21) and (E)-β-(pyrimidin-5-yl)acrylamides (15, 17, 19, and 22)were synthesized as sparsomycin analogs, and their antitumor activity was examined by cell growth inhibition assay against mouse leukemia L5178Y cells in vitro.Synthesis was carried out by condensation of appropriate acids (4, 6, 10, and 12) and amino acid methyl esters (13) by the mixed anhydride method using isobutyl chlorocarbonate. The condensation product was converted to the corresponding acid and alcohol derivatives by hydrolysis and LiBH4 reduction. The compounds having an ethylene linkage at the C-5 position and an ester moiety at the terminal amino acid functionality (15b, and 17b-g) exhibited remarkable antitumor activity.

  多种吡啶-5-甲酰胺（14、16、18、20 和 21）以及（E）-β-（吡啶-5-基）丙烯酰胺（15、17、19 和 22）作为 sparsomycin 类似物被合成，并通过体外细胞生长抑制试验检测其对小鼠白血病 L5178Y 细胞的抗肿瘤活性。合成方法是使用异丁基氯甲酸酯通过混合酐法将适当的酸（4、6、10 和 12）和氨基酸甲酯（13）缩合。通过水解和 LiBH4 还原，将缩合产物转化为相应的酸和醇衍生物。在 C-5 位带有乙烯键合且末端氨基酸功能团为酯的化合物（15b 和 17b-g）显示出显著的抗肿瘤活性。
• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。